|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2007-6-7
|
|
pubmed:abstractText |
Docetaxel is currently the standard first-line treatment in patients with hormone-refractory prostate cancer (HRPC). Bortezomib, the first proteasome inhibitor in clinical use, demonstrated activity against prostate cancer in phase I trials. For this reason, we evaluated the efficacy of docetaxel plus bortezomib in the first-line treatment of patients with HRPC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1558-7673
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
278-83
|
|
pubmed:meshHeading |
pubmed-meshheading:17553208-Adenocarcinoma,
pubmed-meshheading:17553208-Aged,
pubmed-meshheading:17553208-Aged, 80 and over,
pubmed-meshheading:17553208-Androgens,
pubmed-meshheading:17553208-Antineoplastic Agents,
pubmed-meshheading:17553208-Boronic Acids,
pubmed-meshheading:17553208-Drug Administration Schedule,
pubmed-meshheading:17553208-Humans,
pubmed-meshheading:17553208-Male,
pubmed-meshheading:17553208-Middle Aged,
pubmed-meshheading:17553208-Prostatic Neoplasms,
pubmed-meshheading:17553208-Pyrazines,
pubmed-meshheading:17553208-Taxoids,
pubmed-meshheading:17553208-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
|
|
pubmed:affiliation |
Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA. jhainsworth@tnonc.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
